Han Hye Sung, Koh Young Gue, Kim Ka Ram, Choi Jin Hwa, Park Kui Young
Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea.
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.
Support Care Cancer. 2025 Jan 14;33(2):93. doi: 10.1007/s00520-025-09147-9.
Acute radiation dermatitis (ARD) is a frequent side effect experienced by breast cancer patients undergoing radiotherapy. This study aimed to assess the efficacy and safety of a topical cream containing aminoacryl tRNA synthetase complex interacting 1 (AIMP1)-derived peptide (AdP) in mitigating radiation dermatitis (RD) in breast cancer patients undergoing radiotherapy.
An 8-week single-center, prospective pilot study was conducted to compare the clinical efficacy and safety of an AdP-containing cream with a control cream lacking AdP for the mitigation of RD. Fifteen patients undergoing radiotherapy applied the test cream to the right side and the control cream to the left side of the radiation exposure site, bisected by the nipple line. RD was evaluated at baseline and at weeks 2, 4, 6, and 8, employing the 5-point grading system advocated by the Radiation Oncology Group (RTOG).
The average RTOG score was lower on the test side in comparison to the control side, and a less pronounced increase in melanin index was observed on the test side. However, these differences were not statistically significant. Both sides exhibited increased skin hydration and decreased transepidermal water loss. Analyzing the maximum RTOG scores throughout the study, RD of maximum grades 1 and 2 was noted in 54.5% and 45.5% of patients on the test side. On the control side, the maximum grades 1 and 2 were observed in 45.5% and 54.5% of patients respectively.
The AdP-containing cream did not prove to be more effective than the control cream without AdP in mitigating RD. However, the total incidence of RD in our study was notably lower than previously documented, illustrating the protective effects of both the test and control creams.
急性放射性皮炎（ARD）是接受放疗的乳腺癌患者常见的副作用。本研究旨在评估含氨酰基tRNA合成酶复合体相互作用蛋白1（AIMP1）衍生肽（AdP）的外用乳膏减轻接受放疗的乳腺癌患者放射性皮炎（RD）的疗效和安全性。
进行了一项为期8周的单中心前瞻性试点研究，比较含AdP乳膏与不含AdP的对照乳膏减轻RD的临床疗效和安全性。15例接受放疗的患者将试验乳膏涂抹于放射暴露部位的右侧，对照乳膏涂抹于左侧，以乳头线为界将放射暴露部位一分为二。在基线以及第2、4、6和8周采用放射肿瘤学组（RTOG）倡导的5分分级系统评估RD。
与对照侧相比，试验侧的平均RTOG评分更低，且试验侧观察到的黑色素指数增加不明显。然而，这些差异无统计学意义。两侧均表现出皮肤水合作用增加和经表皮水分流失减少。分析整个研究过程中的最大RTOG评分，试验侧分别有54.5%和45.5%的患者出现最大1级和2级RD。在对照侧，分别有45.5%和54.5%的患者观察到最大1级和2级。
含AdP的乳膏在减轻RD方面并未被证明比不含AdP的对照乳膏更有效。然而，我们研究中RD的总发生率明显低于先前记录，说明试验乳膏和对照乳膏均有保护作用。
